PLEASANTON, Calif., Aug. 24, 2015 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) has signed a definitive asset purchase agreement with Lumora for products associated with the unique, patent-protected Heat Elution1 technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded (FFPE) tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
Today, nucleic acid purification technology from specimens including formalin-fixed tissues can be cumbersome and inefficient. Lumora’s highly differentiated proprietary methodology will enable simple and automated nucleic acid isolation in minutes instead of hours. In addition, the technology is environmentally friendly and can be applied to process a wide variety of sample types including whole blood, fecal matter, sputum, FFPE tissue and buccal swabs.